Shareholders of Silver Hammer Mining Corp., Stroud Resources Ltd., and SilverMark Resources Inc. have overwhelmingly approved their amalgamation to create Silver Frontier Resources Corp. This merger combines their silver assets and expertise to build a larger, diversified, and well-capitalized silver company. The new entity will advance projects like the Santo Domingo Silver-Gold Project in Mexico and expand its portfolio with properties in the U.S. and Morocco. The amalgamation is pending final conditions, including financing completion, marking a significant step toward operational growth and shareholder value creation.
The Silver Hammer and Stroud shareholders' amalgamation news is presented with Pluang's Basic Materials sector data as context. As of Sep 29, 2026 00:02 WIB, 6 of 38 priced US Basic Materials stocks rose while 32 fell. Notable movers include Newmont Corporation (NEM) at USD 116.11 with a -4.38% change and a typical hold time of 58 days on Pluang.
Vertex Pharmaceuticals reported a 12% revenue increase to $3.33 billion in Q2, driven by its dominant cystic fibrosis treatments. UBS raised its price target from $585 to $615, reflecting confidence in Vertex's strong financials and growth potential....
Accenture's stock surged 37.6% recently, driven by rising demand for AI services and new AI-focused offerings. The company outpaced industry growth and secured 100 new clients for advanced AI projects in one quarter. An analyst raised the price targe...
SpaceX, trading near $148 per share with a market cap of about $1.95 trillion, is preparing for Starship's first orbital mission and the deployment of its first operational Starlink V3 satellites. This milestone is key for expanding Starlink's global...
Monarch Casino & Resort received a reiterated Buy rating due to strong EBITDA and free cash flow from its Atlantis and Black Hawk properties. Analyst Pedro Goulart highlights a 20% upside target of $147 per share, supported by Reno's tourism momentum...
Johnson & Johnson is poised for growth with a strong oncology and immunology pipeline, including promising drugs like CARVYKTI and TREMFYA showing significant progress. The company reported a 56% stock rally over the past year and raised earnings gui...
